Full Press Release Details
MARLBOROUGH, Mass. , July 22, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has initiated full commercial launch of the new POLARIS™ Imaging System. This system will support the Boston Scientific family of intravascular ultrasound (IVUS) catheters, including coronary, peripheral and intra-cardiac echo products. The POLARIS System offers enhanced ease-of-use and more powerful processing capabilities. Its modular design would also support the planned release of new Boston Scientific imaging products including a fractional flow reserve (FFR) wire, a new family of IVUS catheters, enhanced software features and better system control tools.
The POLARIS System has CE Mark and FDA 510(k) clearance. It has been evaluated in numerous hospitals in the U.S. and Europe , and was showcased during live cases at the EuroPCR conference in May.
"The POLARIS System is an advance for intravascular imaging," said Lowell Satler , M.D., director of Coronary Interventions, MedStar Washington Hospital Center in Washington , D.C. "The improved ease-of-use and image processing simplifies the procedure and enables our team to quickly obtain the information needed to treat patients."
Boston Scientific will offer customers an opportunity to upgrade their existing iLab System to the state-of-the-art POLARIS System.
"There are overwhelming data demonstrating that using IVUS improves patient outcomes," said Isaac Zacharias , vice president and general manager, Imaging, Boston Scientific. "The POLARIS System represents the ongoing commitment of Boston Scientific to develop products that improve patient outcomes by providing physicians improved IVUS guidance in their daily practice."
About Boston Scientific Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook .
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans, new product launches and anticipated future use, clinical trials, product performance and impact, and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
CONTACT: Media: Ryan Davenport Global Media Relations Boston Scientific Corporation 763-494-2664 (office) [email protected]
Simonetta Balbi PR and Corporate Communication EMEA Boston Scientific Corporation + 39 3387936422 (mobile) + 39 0106060281 (direct) [email protected]
Susie Lisa , CFA Investor Relations Boston Scientific Corporation 508-683-5565 (office) [email protected]
SOURCE Boston Scientific Corporation